Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

J. W. C. Alffenaar*, T. van der Laan, S. Simons, T. S. van der Werf, P. J. van de Kasteele, H. de Neeling, D. van Soolingen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Scopus)

Abstract

Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug-and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Original languageEnglish
Pages (from-to)1287-1289
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number3
DOIs
Publication statusPublished - Mar-2011

Keywords

  • MULTIDRUG-RESISTANT TUBERCULOSIS
  • MITOCHONDRIAL PROTEIN-SYNTHESIS
  • MURINE MODEL
  • OXAZOLIDINONES
  • PHARMACOKINETICS
  • TOLERABILITY
  • INHIBITION
  • EFFICACY
  • DRUGS

Cite this